AVEO Pharma

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

AVEO Pharmaceuticals (AVEO) suffers a major setback as it delays the NDA filing for Fotivda in the United States.

AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

AVEO (AVEO) Down 19.9% Since Last Earnings Report: Can It Rebound?

AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.

AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Pharmaceuticals (AVEO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

In the latest trading session, AVEO Pharmaceuticals (AVEO) closed at $0.91, marking a -1.42% move from the previous day.

AVEO Pharmaceuticals (AVEO) Dips More Than Broader Markets: What You Should Know

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

As of late, it has definitely been a great time to be an investor in AVEO Pharmaceuticals.

Will AVEO Pharmaceuticals Continue to Surge Higher?

AVEO (AVEO) Up 71.1% Since Last Earnings Report: Can It Continue?

AVEO Pharmaceuticals (AVEO) closed at $1.10 in the latest trading session, marking a +1.85% move from the prior day.

AVEO Pharmaceuticals (AVEO) Outpaces Stock Market Gains: What You Should Know

AstraZeneca

A recent Seeking Alpha blog post from BlueLion reported that several U.S. investment banks believed AstraZeneca will acquire AVEO at price tag of $800M to $1.2B.

AVEO Acquisition Rumors Resuscitate The Stock

AVEO Pharmaceuticals (AVEO) focuses on the NDA for Fotivda in the United States for the treatment of advanced or metastatic RCC.

AVEO Pharmaceuticals (AVEO) to File NDA for Fotivda with FDA

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

News for AVEO Pharma Stock (AVEO)